BrightSpring Health Services Announces CareMed Was Selected as a National Specialty Pharmacy Partner for Leqembi®
BrightSpring Health Services (NASDAQ: BTSG) announced that its subsidiary CareMed has been selected by Eisai as a national specialty pharmacy provider for Leqembi®, an innovative Alzheimer's disease treatment. The FDA-approved medication demonstrated effectiveness in slowing cognitive impairment progression over 18 months in Phase III clinical trials involving 1,795 patients aged 50-90 with early Alzheimer's disease. Leqembi is a monoclonal antibody targeting aggregated forms of amyloid beta, showing superior results compared to placebo in treating mild cognitive impairment and mild dementia stages.
BrightSpring Health Services (NASDAQ: BTSG) ha annunciato che la sua filiale CareMed è stata selezionata da Eisai come fornitore nazionale di farmacia specializzata per Leqembi®, un trattamento innovativo per la malattia di Alzheimer. Il medicinale approvato dalla FDA ha dimostrato efficacia nel rallentare la progressione del deterioramento cognitivo per 18 mesi in studi clinici di Fase III che hanno coinvolto 1.795 pazienti di età compresa tra 50 e 90 anni con malattia di Alzheimer precoce. Leqembi è un anticorpo monoclonale che mira a forme aggregate di beta-amiloide, mostrando risultati superiori rispetto al placebo nel trattamento delle fasi di lieve deterioramento cognitivo e demenza lieve.
BrightSpring Health Services (NASDAQ: BTSG) anunció que su subsidiaria CareMed ha sido seleccionada por Eisai como proveedor nacional de farmacias especializadas para Leqembi®, un tratamiento innovador para la enfermedad de Alzheimer. El medicamento aprobado por la FDA demostró eficacia en frenar la progresión del deterioro cognitivo durante 18 meses en ensayos clínicos de Fase III que involucraron a 1,795 pacientes de entre 50 y 90 años con Alzheimer en etapa temprana. Leqembi es un anticuerpo monoclonal que se dirige a formas agregadas de beta amiloide, mostrando resultados superiores en comparación con el placebo en el tratamiento de las etapas de leve deterioro cognitivo y demencia leve.
BrightSpring Health Services (NASDAQ: BTSG)는 자회사 CareMed가 Eisai에 의해 Leqembi®의 국가 전문 약국 공급자로 선정되었다고 발표했습니다. FDA에서 승인된 이 약물은 초기 알츠하이머 병을 앓고 있는 50-90세의 1,795명을 대상으로 한 3상 임상 시험에서 18개월 동안 인지 기능 저하 진행을 늦추는 효과를 입증했습니다. Leqembi는 응집된 형태의 아밀로이드 베타를 대상으로 하는 단일클론 항체로, 경미한 인지 손상 및 경미한 치매 단계 치료에서 위약 대비 우수한 결과를 보여주었습니다.
BrightSpring Health Services (NASDAQ: BTSG) a annoncé que sa filiale CareMed a été sélectionnée par Eisai en tant que fournisseur national de pharmacie spécialisée pour Leqembi®, un traitement innovant contre la maladie d'Alzheimer. Ce médicament approuvé par la FDA a démontré son efficacité à ralentir la progression de la dégradation cognitive sur 18 mois lors d'essais cliniques de phase III impliquant 1 795 patients âgés de 50 à 90 ans souffrant d'Alzheimer précoce. Leqembi est un anticorps monoclonal ciblant les formes agrégées de bêta-amyloïde, montrant des résultats supérieurs par rapport au placebo dans le traitement des stades de déclin cognitif léger et de démence légère.
BrightSpring Health Services (NASDAQ: BTSG) gab bekannt, dass ihre Tochtergesellschaft CareMed von Eisai als nationaler Anbieter für spezialisierte Apotheken für Leqembi®, eine innovative Behandlung der Alzheimer-Krankheit, ausgewählt wurde. Das von der FDA zugelassene Medikament hat sich in einer 18-monatigen Phase-III-Studie mit 1.795 Patienten im Alter von 50-90 Jahren, die an frühzeitiger Alzheimer-Krankheit leiden, als wirksam erwiesen, um die Progression der kognitiven Beeinträchtigung zu verlangsamen. Leqembi ist ein humaner monoklonaler Antikörper, der auf aggregierte Formen von Beta-Amyloid abzielt und im Vergleich zu Placebo überlegene Ergebnisse bei der Behandlung von leichtem kognitivem Verfall und leichtem Demenzstadium zeigt.
- Selected as national specialty pharmacy provider for innovative Alzheimer's treatment Leqembi®
- Partnership with major pharmaceutical company Eisai expands market presence
- Adds high-value specialty medication to product portfolio
- None.
Insights
The selection of CareMed as a national specialty pharmacy partner for Leqembi represents a significant business opportunity for BrightSpring Health Services. Leqembi, with its proven efficacy in slowing cognitive decline in Alzheimer's patients, has substantial market potential given the large and growing Alzheimer's patient population. The specialty pharmacy distribution rights for this breakthrough treatment could generate meaningful revenue streams, as specialty drugs typically command higher margins than traditional pharmaceuticals.
The partnership with Eisai enhances BrightSpring's market position in the competitive specialty pharmacy sector and demonstrates the company's ability to secure high-value distribution agreements. With approximately 6.7 million Americans living with Alzheimer's, the addressable market for Leqembi is substantial. This deal strengthens CareMed's portfolio in the neurology space and could lead to additional partnership opportunities with other pharmaceutical manufacturers.
LOUISVILLE, Ky., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) is proud that CareMed, a BrightSpring company and leading independent Specialty Pharmacy, was selected by Eisai to be the national specialty pharmacy provider for Leqembi®, a cutting-edge treatment for Alzheimer’s disease.
“We’re proud of the work CareMed is doing with manufacturers and prescribers to improve and extend the lives of patients living with mild cognitive impairment and dementia, bringing more treatment options to Alzheimer’s disease,” said BrightSpring’s President and CEO, Jon Rousseau. “CareMed’s partnership with Eisai shows their strong commitment to increasing patient access to innovative medications and treatments, while delivering comprehensive support and care to patients and their loved ones."
Leqembi is a monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta in the treatment of Alzheimer’s disease. The medication was tested in numerous clinical trials with patients diagnosed with mild cognitive impairment or mild dementia stage of disease. The FDA approval of Leqembi is based on the results of the Phase III clinical trial, which compared Leqembi to placebo in patients 50 to 90 years of age with early Alzheimer’s disease. The study randomized 1795 patients in a 1:1 ratio to receive either intravenous Leqembi or placebo. Patients who received Leqembi showed slowed progression of cognitive impairment over an 18-month period compared to those taking the placebo.
“At CareMed, we’re constantly looking for new opportunities to expand our portfolio of breakthrough treatments and therapies for patients living with devastating diseases,” said Benito Fernandez, Chief Commercial Officer. “We’re proud to be in the specialty pharmacy network for Leqembi. We’re confident this new medication will help more patients with Alzheimer’s get the right treatment to improve their quality of life.”
To learn more about CareMed and BrightSpring, please visit https://www.brightspringhealth.com/.
About BrightSpring Health Services:
BrightSpring Health Services provides complementary and integrated home- and community-based pharmacy and health solutions for complex populations in need of specialized and/or chronic care. Through the Company’s service lines, including pharmacy, home health care and primary care, and rehabilitation and behavioral health, we provide comprehensive care and clinical solutions in all 50 states to over 400,000 customers, clients and patients daily.
About CareMed Specialty Pharmacy:
CareMed is an independent Specialty Pharmacy and clinical support services company within the BrightSpring enterprise. CareMed was founded to bring together the stakeholders involved in the chronic and rare disease treatment process and serve the specialized needs of patients, providers, hospitals, manufacturers, health plans, and payers. CareMed is headquartered in New Hyde Park, New York, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. It is accredited through URAC, ACHC, and NAPB as a Digital Pharmacy. For more information about CareMed, please visit CareMedSP.com.
Media Contact
Leigh White
Leigh.white@brightspringhealth.com
502.630.7412
FAQ
What is BrightSpring Health Services' (BTSG) role in distributing Leqembi?
What were the results of Leqembi's Phase III clinical trials for BrightSpring (BTSG)?
How will the Eisai partnership affect BrightSpring's (BTSG) specialty pharmacy business?
